Factors affecting warfarin dose requirements and quality of anticoagulation in adult Egyptian patients: Role of gene polymorphism

Irish Journal of Medical Science

Volumn 183, Issue 2, 2014, Pages 161-172

  Bazan, N S ^a   Sabry, N A ^a   Rizk, A ^b   Mokhtar, S ^b   Badary, O A ^c  

^a CAIRO UNIVERSITY   (Egypt)

^b CAIRO UNIVERSITY   (Egypt)

^c African Union Organization St Abbassia   (Egypt)

Author keywords

Allele frequency; Egyptians; Genotyping; Pharmacogenetics; Race; Warfarin

Indexed keywords

ADULT; AGE FACTORS; AGED; ALLELES; ANTICOAGULANTS; ARYL HYDROCARBON HYDROXYLASES; EGYPT; FEMALE; GENOTYPE; HUMANS; INDIVIDUALIZED MEDICINE; INTERNATIONAL NORMALIZED RATIO; LINEAR MODELS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; REGRESSION ANALYSIS; SMOKING; THROMBOEMBOLISM; VITAMIN K EPOXIDE REDUCTASES; WARFARIN; YOUNG ADULT;

EID: 84905163599     PISSN: 00211265     EISSN: 18634362     Source Type: Journal    
DOI: 10.1007/s11845-013-0978-y     Document Type: Article

References (69)

1. Qiang M, Anthony YHL (2011) Pharmacogenetics, pharmacogenomics, and individualized medicine. Pharmacol Rev 63(2):437-459
2. Corley SD, Epstein AE, DiMarco JP et al (2004) Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study. Circulation 109:1509-1513 (Pubitemid 38420179)
3. James AH, Britt RP, Risking CL et al (1992) Factors affecting the maintenance dose of warfarin. J Clin Pathol 45:704-706
4. Hallak HO, Wedlund PJ, Modi MW et al (1993) High clearance of (S)-warfarin resistant subject. Br J Clin Pharmacol 35:327-330 (Pubitemid 23074065)
5. Suriapranata IM, Tjong WY, Wang T et al (2011) Genetic factors associated with patient-specific warfarin dose in ethnic Indonesians. BMC Med Genet 12:80
6. Loebstein R, Yonath H, Peleg D et al (2001) Interindividual variability in sensitivity to warfarin-nature or nurture? Clin Pharmacol Ther 70:159-164
7. Hillman MA, Wilke RA, Caldwell MD et al (2004) Relative impact of covariates in prescribing warfarin according to CYP2C9 genotype. Pharmacogenetics 14:539-547 (Pubitemid 39100005)
8. Kamali F, Khan TI, King BP et al (2004) Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin. Clin Pharmacol Ther 75:204-212 (Pubitemid 38314870)
9. Franco V, Polanczyk CA, Clausell N et al (2004) Role of dietary vitamin K intake in chronic oral anticoagulation: prospective evidence from observational and randomized protocols. Am J Med 116:651-656 (Pubitemid 38581109)
10. Blann A, Hewitt J, Siddiqui F et al (1999) Racial background is a determinant of average warfarin dose required to maintain the INR between 2.0 and 3.0. Br J Haematol 107:207-209 (Pubitemid 29500828)
11. Absher RK, Moore ME, Parker MH (2002) Patient-specific factors predictive of warfarin dosage requirements. Ann Pharmacother 36:1512-1517
12. Gan GG, Teh A, Goh KY et al (2003) Racial background is a determinant factor in the maintenance dosage of warfarin. Int J Hematol 78:84-86 (Pubitemid 36899909)
13. Takahashi H, Wilkinson GR, Caraco Y et al (2003) Population differences in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients. Clin Pharmacol Ther 73:253-263 (Pubitemid 36269676)
14. Miao L, Yang J, Huang C et al (2007) Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients. Eur J Clin Pharmacol 63(12):1135-1141 (Pubitemid 350112769)
15. Gage BF, Lesko LJ (2008) Pharmacogenetics of warfarin: regulatory, scientific, and clinical issues. J Throm Thrombolysis 25: 45-51
16. Yin T, Miyata T (2007) Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1-rationale and perspectives. Thromb Res 120(1):1-10 (Pubitemid 46601582)
17. Cho HJ, Sohn KH, Park HM et al (2007) Factors affecting the interindividual variability of warfarin dose requirement in adult Korean patients. Pharmacogenomics 8(4):329-337
18. Furuya H, Fernandez-Salguero P, Gregory W et al (1995) Genetic polymorphisms of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy. Pharmacogenetics 5:389-392 (Pubitemid 26010117)
19. Linder MW, Looney S, Adams JE et al (2002) Warfarin dose adjustments based on CYP2C9 genetic polymorphisms. J Thromb Thrombolysis 14:227-232 (Pubitemid 37069306)
20. Aquilante CL, Langaee TY, Lopez LM et al (2006) Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2 C9 gene polymorphism on warfarin dose requirements. Clin Pharmacol Ther 79:291-302
21. Lefferts JA, Schwab MC, Dandamudi UB et al (2010) Warfarin genotyping using three different platforms. Am J Transl Res 2(4):441-446
22. Rieder MJ, Reiner AP, Gage BF et al (2005) Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 352:2285-2293 (Pubitemid 40740552)
23. Wadelius M, Chen LY, Downes K et al (2005) Common VKORC1 and GGCX polymorphisms associated with warfarin dose. Pharmacogenomics J 5:262-270 (Pubitemid 41131718)
24. Schalekamp T, Brasse BP, Roijers JFM et al (2006) VKORC1 and CYP2C9 genotypes and acenocoumarol anticoagulation status: interaction between both genotypes affects overanticoagulation. Clin Pharmacol Ther 80(1):13-22 (Pubitemid 43964915)
25. Takahashi H, Wilkinson GR, Nutescu EA et al (2006) Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans. Pharmacogenet Genom 16:101-110 (Pubitemid 43145678)
26. Declaration of Helsinki. World Medical Association. http://www.wma.net/ en/30publications/10policies/b3/. Accessed Jan 2013
27. Sohn S, Savova GK (2009) Mayo clinic smoking status classification system: extensions and improvements. AMIA Annu Symp Proc 2009:619-623
28. Lima MV, Ribeiro GS, Mesquita ET et al (2008) CYP2C9 genotypes and the quality of anticoagulation control with warfarin therapy among Brazilian patients. Eur J Clin Pharmacol 64:9-15
29. Beyth RJ, Quin L, Landefeld CS (2000) A multicomponent intervention to prevent major bleeding complications in older patients receiving warfarin. A randomized controlled trial. Ann Intern Med 133(9):687-695
30. Shahin MHA, Khalifa SI, Gong Y et al (2011) Genetic and nongenetic factors associated with warfarin dose requirements in Egyptian patient. Pharmacogenet Genom 21:130-135
31. Hamdy SI, Hiratsuka M, Narahara K et al (2002) Allele and genotype frequencies of polymorphic cytochromes P-450 (CYP2C9, CYP2C19, CYP2E1) and dihydropyrimidine dehydrogenase (DPYD) in the Egyptian population. Br J Clin Pharmacol 53(6):596-603 (Pubitemid 34621785)
32. El-Din MS, Amin DG, Ragab SB et al (2012) Frequency of VKORC1 (C1173T) and CYP2C9 genetic polymorphisms in Egyptians and their influence on warfarin maintenance dose: proposal for a new dosing regimen. Int J Lab Hematol 34(5):517-524
33. Wu AH, Wang P, Smith A et al (2008) Dosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multiethnic population: comparison with other equations. Pharmacogenomics 9(2):169-178 (Pubitemid 351566941)
34. Sconce EA, Khan TI, Wynne HA et al (2005) The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 106(7):2329-2333 (Pubitemid 41510803)
35. Stubbins MJ, Harries LW, Smith G et al (1996) Genetic analysis of the human cytochrome P450 CYP2C9 locus. Pharmacogenetics. 6(5):429-439 (Pubitemid 26380099)
36. Sipeky C, Lakner L, Szabo M et al (2009) Interethnic differences of CYP2C9 alleles in healthy Hungarian and Roma population samples: relationship to worldwide allelic frequencies. Blood Cells Mol Dis 43(3):239-242
37. Tanira MO, Al-Mukhaini MK, Al-Hinai AT et al (2007) Frequency of CYP2C9 genotypes among Omani patients receiving warfarin and its correlation with warfarin dose. Community Genet 10(1):32-37 (Pubitemid 46005799)
38. Yousef AM, Bulatova NR, Newman W et al (2012) Allele and genotype frequencies of the polymorphic cytochrome P450 genes (CYP1A1, CYP3A4, CYP3A5, CYP2C9 and CYP2C19) in the Jordanian population. Mol Biol Rep 39(10):9423-9433
39. Namazi S, Azarpira N, Hendijani F et al (2010) The impact of genetic polymorphisms and patient characteristics on warfarin dose requirements: a cross-sectional study in Iran. Clin Ther 32(6):1050-1060
40. Djaffar-Jureidini I, Chamseddine N, Keleshian S et al (2011) Pharmacogenetics of coumarin dosing: prevalence of CYP2C9 and VKORC1 polymorphisms in the Lebanese Population. Genet Test Mol Biomark 15(11):827-830
41. Oner Ozgon G, Langaee TY, Feng H et al (2008) VKORC1 and CYP2C9 polymorphisms are associated with warfarin dose requirements in Turkish patients. Eur J Clin Pharmacol 64(9):889-894
42. Shrif NE, Won HH, Lee ST et al (2011) Evaluation of the effects of VKORC1 polymorphisms and haplotypes, CYP2C9 genotypes, and clinical factors on warfarin response in Sudanese patients. Eur J Clin Pharmacol 67(11):1119-1130
43. Yuan HY, Chen JJ, Lee MT et al (2005) A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. Hum Mol Genet 14(13):1745-1751 (Pubitemid 41430097)
44. Yoshizawa M, Hayashi H, Tashiro Y et al (2009) Effect of VKORC1-1639G>A polymorphism, body weight, age, and serum albumin alterations on warfarin response in Japanese patients. Thromb Res 124(2):161-166
45. Gan GG, Phipps ME, Lee MM et al (2011) Contribution of VKORC1 and CYP2C9 polymorphisms in the interethnic variability of warfarin dose in Malaysian populations. Ann Hematol 90(6):635-641
46. Scibona P, Redal MA, Garfi LG et al (2012) Prevalence of CYP2C9 and VKORC1 alleles in the Argentine population and implications for prescribing dosages of anticoagulants. Genet Mol Res 11(1):70-76
47. Bravo-Villalta HV, Yamamoto K, Nakamura K et al (2005) Genetic polymorphism of CYP2C9 and CYP2C19 in a Bolivian population: an investigative and comparative study. Eur J Clin Pharmacol 61(3):179-184 (Pubitemid 40768549)
48. Verstuyft C, Robert A, Morin S et al (2003) Genetic and environmental risk factors for oral anticoagulant overdose. Eur J Clin Pharmacol 58(11):739-745 (Pubitemid 36399230)
49. Johnson JA, Gong L, Whirl-Carrillo M et al (2011) Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Clin Pharmacol Ther 90(4):625-629
50. Rathore SS, Agarwal SK, Pande S et al (2011) The impact of VKORC1-1639G>A polymorphism on the maintenance dose of oral anticoagulants for thromboembolic prophylaxis in North India: a pilot study. Indian J Hum Genet 17(4):54-57
51. Kimura R, Miyashita K, Kokubo Y et al (2007) Genotypes of vitamin K epoxide reductase, gamma-glutamyl carboxylase, and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patients. Thromb Res 120(2):181-186 (Pubitemid 46754413)
52. Schelleman H, Chen Z, Kealey C et al (2007) Warfarin response and vitamin K epoxide reductase complex 1 in African Americans and Caucasians. Clin Pharmacol Ther 81:742-747 (Pubitemid 46625114)
53. Yamazaki H, Inoue K, Chiba K et al (1998) Comparative studies on the catalytic roles of cytochrome P450 2C9 and its Cys- and Leu-variants in the oxidation of warfarin, flurbiprofen, and diclofenac by human liver microsomes. Biochem Pharmacol 56(2):243-251 (Pubitemid 28479833)
54. Kirchheiner J, Brockmöller J (2005) Clinical consequences of cytochrome P4502C9 polymorphisms. Clin Pharmacol Ther 77(1):1-16 (Pubitemid 40089477)
55. D'Andrea G, D'Ambrosio RL, Di Perna P et al (2005) A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood 105(2):645-649 (Pubitemid 40070748)
56. Stehle S, Kirchheiner J, Lazar A et al (2008) Pharmacogenetics of oral anticoagulants: a basis for dose individualization. Clin Pharmacokinet 47(9):565-594
57. Higashi MK, Veenstra DL, Kondo LM et al (2002) Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 287(13):1690-1898
58. Nasu K, Kubota T, Ishizaki T (1997) Genetic analysis of CYP2C9 in a Japanese population. Pharmacogenetics 7(5):405-409 (Pubitemid 27427552)
59. Cavallari LH, Shin J, Perera MA (2011) Role of pharmacogenomics in the management of traditional and novel oral anticoagulants. Pharmacotherapy 31(12):1192-1207
60. Scordo MG, Caputi AP, D'Arrigo C et al (2004) Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population. Pharmacol Res 50:195-200 (Pubitemid 38737252)
61. Yoon YR, Shon JH, Kim MK et al (2001) Frequency of cytochrome P4502C9 mutant alleles in a Korean population. Br J Clin Pharmacol 51:277-280
62. Lee SC, Ng SS, Oldenburg J et al (2006) Interethnic variability of warfarin maintenance requirements explained by VKORC1 genotype in an Asian population. Clin Pharmacol Ther 79:197-205
63. Yang L, Ge W, Yu F et al (2010) Impact of VKORC1 gene polymorphism on interindividual and interethnic warfarin dosage requirement - a systematic review and meta-anlaysis. Thromb Res 125(4):e159-e166
64. Voora D, Eby C, Linder MW et al (2005) Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype. Thromb Haemost 93(4):700-705 (Pubitemid 40485406)
65. Limdi NA, McGwin G, Goldstein JA et al (2008) Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin. Clin Pharmacol Ther 83(2):312-321
66. Takeuchi F, McGinnis R, Bourgeois S et al (2009) A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet 5(3):e1000433
67. Schwarz UI, Ritchie MD, Bradford Y et al (2008) Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med 358(10):999-1008 (Pubitemid 351347099)
68. Meckley LM, Wittkowsky AK, Rieder MJ et al (2008) An analysis of the relative effects of VKORC1 and CYP2C9 variants on anticoagulation related outcomes in warfarin-treated patients. Thromb Haemost 100(2):229-239
69. Wadelius M, Chen LY, Lindh JD et al (2009) The largest prospective warfarin-treated cohort supports genetic forecasting. Blood 113(4):784-792